The Life Sciences team advised Isomorphic Labs on a strategic, cross-modality, multi-target research collaboration with Johnson & Johnson*. The collaboration leverages Isomorphic’s AI-first approach to drug discovery with Johnson & Johnson’s expertise in drug discovery and development. Under the collaboration, Isomorphic Labs will be responsible for in silico predictions and design, while Johnson & Johnson will conduct experimental assays and assume responsibility for advancing programs through development.
The Goodwin team was led by Noelle Dubiansky and Katerina Stavrianidis and consisted of John Yates, Evan De Ycaza, Daniel Karelitz, Eram Khan, and Bethany Withers.
For more information on the deal, please read Isomorphic Labs’ post and coverage in Endpoints News. For more information on Isomorphic Labs, please visit their website.
*Legal entity: Janssen Biotech, Inc